Products
Pre-made Tomuzotuximab benchmark antibody ( Whole mAb, anti-EGFR therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-586
Pre-Made Tomuzotuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tomuzotuximab (previously known as CetuGEX) is a novel immune-enhanced monoclonal antibody (mAb) against the epidermal growth factor receptor (EGFR). It is a glycoengineered second generation antibody of cetuximab produced in the human GlycoExpress expression system (Glycotope).
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-586-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Tomuzotuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody |
| INN Name | Tomuzotuximab |
| Target | EGFR |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC/5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC |
| 95-98% SI Structure | 5gz0:BA:DC/6arp:BA:DC/6aru:CB |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Glycotope |
| Conditions Approved | na |
| Conditions Active | Head and neck cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Renal cancer;Solid tumours |
| Conditions Discontinued | na |
| Development Tech | GlycoExpress Technology |
